BIOMERICA INC (BMRA)
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Sector: In Vitro & In Vivo Diagnostic Substances
Industry: Medical - Devices
Biomerica, Inc.
1-25 of 605 filings
Recent SEC filings with analysis
- 10-QBiomerica's fiscal Q1 (August 31, 2026) 10-Q raises substantial doubt about the company's ability to continue as a going concern, with management stating that…
- 8-KBiomerica director David Moatazedi has informed the Board he will not stand for re-election at the December 11, 2026 annual meeting.
- S-3Biomerica filed a $250 million shelf registration covering common stock, preferred stock, debt securities, and warrants, enabling takedowns at any time.
- S-3Biomerica filed an S-3 shelf registration covering the resale of up to 1,403,705 shares of common stock by selling stockholders.